Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 574 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents
 2
Introduction 7
Type 1 Diabetes (Juvenile Diabetes) - Overview 8
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development 9
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 37
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 50
Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles 103
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 529
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 537
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 539
Appendix 548

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols SA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ixchel Pharma LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production SpA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Melior Discovery Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Neovacs SA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sotio AS, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Tetragenetics Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes LLC, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Traverse Biosciences Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte Inc, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corp, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zealand Pharma AS, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..6), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2017 (Contd..7), H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2017
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2017 (Contd..1), H1 2017